Mithra Announces Further Positive Phase IIb Donesta® Efficacy and Safety Data

  • Further analysis of the E4 Relief dose-finding study shows a statistically significant reduction in the severity of VMS (hot flushes) at the optimal minimum dose (15 mg  E4)
  • Data reinforce the previously announced positive Phase IIb Donesta® results, demonstrating a meaningful and statistically significant reduction in the frequency of VMS
  • Encouraging cardiovascular safety profile further confirmed by hemostatic, glucose and  lipid markers
  • Data will be presented at the International Menopause Society Conference on 8 June 2018
Liège, Belgium, 30 May 2018, 16:06 CET – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announces further positive topline data from the E4 Relief Phase II study of Donesta® for the treatment of Vasomotor Symptoms (VMS), and in particular hot flushes relief, in post-menopausal women. Donesta® is Mithra’s next-generation hormone therapy (HT) candidate with oral administration of Estetrol (E4).